

CLAIMS

1. An anti-human vascular endothelial growth factor (hVEGF) antigen-binding fragment produced by human retinal cells.
2. The anti-hVEGF antigen-binding fragment of claim 1, which is produced by human photoreceptor cells.
3. The anti-hVEGF antigen-binding fragment of claim 1 or 2, which is glycosylated.
4. The anti-hVEGF antigen-binding fragment of claim 3, which contains a α 2,6-sialylated glycan.
5. The anti-hVEGF antigen-binding fragment of claim 3 or 4, which does not contain NeuGc.
6. The anti-hVEGF antigen-binding fragment of any one of claims 1-5, which contains a tyrosine-sulfation.
7. A glycosylated anti-hVEGF antigen-binding fragment, which:
 - (a) contains a α 2,6-sialylated glycan;
 - (b) does not contain NeuGc; and/or
 - (c) contains a tyrosine-sulfation.
8. An anti-hVEGF antigen-binding fragment, which contains a tyrosine-sulfation.
9. The anti-hVEGF antigen-binding fragment or the glycosylated anti-hVEGF antigen-binding fragment of any one of claims 1-8, which is a Fab.
10. The anti-hVEGF antigen-binding fragment or the glycosylated anti-hVEGF antigen-binding fragment of any one of claims 1-8, which is a F(ab')₂.
11. The anti-hVEGF antigen-binding fragment or the glycosylated anti-hVEGF antigen-binding fragment of any one of claims 1-8, which is a single chain variable domain (scFv).
12. The anti-hVEGF antigen-binding fragment or the glycosylated anti-hVEGF antigen-binding fragment of any one of claims 1-10, which comprises a heavy chain comprising the amino acid sequence of SEQ ID NO. 1 or SEQ ID NO. 3, and a light chain comprising the amino acid sequence of SEQ ID NO. 2, or SEQ ID NO. 4.
13. The anti-hVEGF antigen-binding fragment or the glycosylated anti-hVEGF antigen-binding fragment of any one of claims 1-12, which comprises light chain CDRs 1-3 of SEQ ID NOs: 14-16 and heavy chain CDRs 1-3 of SEQ ID NOs: 17-19 or SEQ ID NOs: 20, 18, and 21.

14. The anti-VEGF antigen-binding fragment or the glycosylated anti-hVEGF antigen-binding fragment of any one of claims 1-13, which is expressed from an AAV8-based viral vector.

15. Use of an anti-hVEGF antigen-binding fragment or a glycosylated anti-hVEGF antigen-binding fragment of any one of claims 1-14 in the manufacture of a medicament for the treatment of a human subject diagnosed with neovascular age-related macular degeneration (nAMD), wherein the medicament is to be administered to the retina of said human subject.